Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134603 | 0.91 | MGLL (0.36) | MGLLCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL6744910 | 0.91 | MEN1 (0.37) | MGLLCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL10134612 | 0.90 | ALDH1A1 (0.37) | MGLLCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL6744725 | 0.83 | KDM4E (0.37) | MGLLALDH1A1GAAKDM4E | |
| SCHEMBL12202857 | 0.82 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1GAAKDM4E | |
| SCHEMBL6744920 | 0.80 | KDM4E (0.32) | MGLLCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL10134599 | 0.80 | CYP4F2 (0.38) | MGLLCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL6796127 | 0.79 | MEN1 (0.37) | MGLLCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL10134595 | 0.79 | MGLL (0.36) | MGLLCYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL6744914 | 0.79 | MEN1 (0.37) | MGLLCYP4F2CYP4A11ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | MGLL 2051/4885CYP4F2 1485/4885CYP4A11 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.